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012.08.00Abstract Aim of the work: To identify the frequency of shrinking lung syndrome (SLS) in sys-
temic lupus erythematosus (SLE) with dyspnea and study the clinical characteristics and differences
in disease activity and damage.
Patients and methods: The study included 47 SLE patients complaining of dyspnea. SLS was
considered in those with exertional dyspnea, restrictive pulmonary function tests (PFTs) and ele-
vated copula of the diaphragm. Full history taking, thorough clinical examination, laboratory
and relevant radiological investigations were performed for all the patients. Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborating Clinics
(SLICC) indices were compared. High resolution CT chest was performed for patients with radio-
logical ﬁndings consistent with SLS.
Results: The mean age of the patients was 29.43 ± 7.45 years, mean disease duration
5.18 ± 3.62 years. The SLS was present in 8 patients (17.02%). There was bilateral elevation of
the diaphragm copulae in 25% of SLS patients and two had associated basal atelectatic bands.
The serum uric acid was signiﬁcantly higher in those with SLS while the 24 h urine protein was sig-
niﬁcantly lower and C4 normalized. The levels of SLEDAI and SLICC tended to be lower in those
with SLS, yet there was no signiﬁcant difference from those without. The demographic features,
clinical and laboratory manifestations, disease activity and damage scores, PFTs and radiological
ﬁndings of the SLE patients are presented.
Conclusion: In SLE patients with dyspnea, SLS should be looked for as it is present in a high
proportion of cases.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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31. Introduction
Systemic lupus erythematosus is an autoimmune systemic
disease that commonly affects the respiratory system [1].
In spite of being frequent, the diagnosis may be difﬁcult be-
cause of the diversity of anatomical and clinical presenta-uction and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
180 T.A. Gheita et al.tions. Proper diagnosis is important as new immunosuppres-
sive drugs have considerably improved the prognosis [2]. At
some time during their course, most patients with SLE show
signs of involvement of the lung, its vasculature, the pleura,
and/or the diaphragm [3]. Pleurisy, coughing, and/or dysp-
nea are often the ﬁrst clues either to lung involvement or
to SLE itself [4].
The respiratory system is commonly compromised in SLE.
The most prevalent presentation includes pleuritis. Other infre-
quent manifestations include interstitial lung disease (ILD),
acute lupus pneumonitis, diffuse alveolar hemorrhage, pul-
monary arterial hypertension, acute reversible hypoxemia
and shrinking lung syndrome (SLS). As survival in lupus pa-
tients has improved over years, avoiding pulmonary damage
emerges as a crucial aim [5]. Respiratory complications of
SLE are relatively common as the initial manifestation and
>50% have pulmonary involvement at some stage of disease
progression [6,7].
In SLE patients, dyspnea is common, frequently disabling
and associated with a history of lupus involvement of the lung
[4]. As it is a complex systemic disease, patients can manifest
dyspnea for primary causes due to SLE itself or secondary to
concomitant complications [8].
Shrinking lung syndrome is a rare respiratory complica-
tion associated with SLE. Patients present with dyspnea
alone or associated with chest pain, lung volume reduction
with no parenchymal abnormalities and a restrictive ventila-
tory defect on pulmonary function tests. The pathogenesis,
treatment, and prognosis of SLS remain controversial.
[1,9]. It has also been reported as a rare complication of sys-
temic autoimmune diseases including SLE, Sjo¨gren’s syn-
drome and polymyositis. Shrinking lung syndrome should
be suspected in any patient with an autoimmune disease pre-
senting with unexplained dyspnea. [10]. It is characterized by
the dysfunction of respiratory muscles, especially the dia-
phragm, resulting in dyspnea [6]. Respiratory function tests
demonstrate severe restrictive ventilatory impairment. Chest
X-ray demonstrates elevated hemi diaphragms and com-
puted tomography (CT) shows no evidence of interstitial
ﬁbrosis, signiﬁcant pleural disease or pulmonary emboli
[11,12].
Shrinking lung syndrome may cause signiﬁcant morbidity
and occasionally mortality. Its cause remains controversial
and could be attributed to diaphragmatic weakness or to chest
wall restriction. No deﬁnitive therapy exists; however, cortico-
steroids lessen symptoms and improve pulmonary function in
some patients. [13–15]. Other hypotheses include diaphrag-
matic paralysis secondary to phrenic nerve injury [10,16], dif-
fuse diaphragm ﬁbrosis [17] and limited chest wall expansion
[18]. Imaging reveals the absence of any signiﬁcant parenchy-
mal disease [19]. Pleuritic inﬂammation and pain may have
an important role in the pathogenesis of SLS [10]. A possible
mechanism linking pleural inﬂammation and diaphragm dys-
function may be via a reﬂex inhibition of diaphragmatic acti-
vation [20]. SLS is a cause of pulmonary damage [21] and
corticosteroids are the most common method of treatment
with a generally good prognosis [11].
The aim of the present study was to detect the frequency of
SLS in SLE patients with dyspnea and study their clinical, lab-
oratory and radiological characteristics and differences in dis-
ease activity and damage.2. Patients and methods
The study included 47 SLE patients fulﬁlling the updated ACR
revised criteria for the classiﬁcation of SLE [22]. The patients
were attending the Rheumatology and Internal medicine out-
patient Clinics of the Cairo University Hospitals. The patients
were grouped according to the presence or absence of shrink-
ing lung syndrome (SLS). All patients had symptomatic pul-
monary manifestation in the form of dyspnea. Shrinking
lung syndrome was considered in those with exertional dysp-
nea, restrictive pattern of the pulmonary function tests and ele-
vated copula of the diaphragm on one or both sides. Full
history taking, thorough clinical examination, laboratory and
relevant radiological investigations were performed for all
the patients. High resolution CT chest was performed for pa-
tients with radiological ﬁndings consistent with SLS. Disease
activity was assessed using the Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI) [23] while assessment of or-
gan damage was made using the Systemic Lupus International
Collaborating Clinics/ACR (SLICC/ACR) index [24]. The
study was approved by the local ethics committee and it con-
forms to the standards currently applied in the Cairo Univer-
sity Teaching Hospitals. All patients gave their informed
consent prior to their inclusion in the study.
Statistics: Analysis of data was performed with a statistical
package for the social sciences (SPSS) version 15. Data were
presented as mean ± standard deviation and percentage, med-
ian (min.–max.). Mann–Whitney test was used for the analysis
of two non parametric quantitative data. Correlation was per-
formed by the Spearman correlation coefﬁcient. p value was
considered signiﬁcant if <0.05.
3. Results
The 47 female SLE patients had a mean age of
29.43 ± 7.45 years [27(18–50)] and disease duration of
5.18 ± 3.62 years [5 (0.25–17)]. Shrinking lung syndrome
(SLS) was present in 8 patients (17.02%). The demographic,
clinical and laboratory features, disease activity and damage
scores of the SLE patients with and without SLS are shown
in Table 1. All patients were receiving corticosteroids at a
mean dose of 17.22 ± 11.09 mg/day. Twenty-one patients
were also receiving azathioprine, 24 hydroxychloroquine, 9
cyclophosphamide and 3 mycophenolate moﬁtil. Those with
SLS and 2 without were receiving theophylline tablets
(150 mg/day) for their respiratory manifestations. The mean
steroid dose received by the patients with and without SLS
was insigniﬁcantly different (23.33 ± 14.72 and
16.25 ± 10.33 mg/day respectively, p 0.3).
Dyspnea was present in all the studied SLE patients. In
addition to SLS, other causes of dyspnea included pleurisy in
41, airway obstruction in 2, mild interstitial lung disease with
minimal pleural effusion in 3, upper airway disease in 2 and
respiratory muscle disease in 5. Two patients were asthmatic,
while none had chest infection, pulmonary thromboembolism,
pneumonitis or any concomitant complication that may cause
dyspnea. Plain X-ray and CT of SLS patients are shown in
Figs. 1 and 2. The pulmonary function test results of the 8 pa-
tients with SLS were as follows: Forced Vital Capacity (FVC):
3.01 ± 0.43 L with a percentage predicted of 77.49 ± 7.1;
Table 1 Demographic features, disease activity, damage index, clinical manifestations and laboratory investigations of the SLE
patients with and without SLS.
SLS (8) Without SLS (39) P value
Demographic features (mean ± SD)
Age (years) 30 ± 7.72 29.34 ± 7.51 0.85
Disease duration (years) 7.33 ± 5.68 4.87 ± 3.2 0.34
BMI 26.5 ± 3.15 26.56 ± 3.58 0.97
Disease activity and damage
SLEDAI 6.67 ± 3.56 8.76 ± 6.63 0.27
SLICC 1.67 ± 1.03 1.71 ± 1.62 0.94
Clinical manifestations no. (%)
Mucocutaneous 5(62.5) 23(58.9)
Arthritis 4(50) 27(69.2)
Hematological 4(50) 31(79.5)
Renal 7(87.5) 36(92.3)
Neuropsychiatric 1(16.7) 16(41.0)
Cardiovascular 0(0) 3(7.69)
Antiphospholipid syndrome 1(12.5) 11(28.2)
Sjo¨gren syndrome 1(12.5) 6(12.8)
Fibromyalgia syndrome 3(37.5) 10(25.6)
Laboratory investigations
ESR 1st hour (mmHg) 69.33 ± 30.11 48.63 ± 27.9 0.16
Hemoglobin (g%) 10.02 ± 2.07 10.81 ± 2.22 0.42
WBCs (x103/mm3) 5.32 ± 2.1 6.53 ± 3.23 0.26
Platelets (x103/mm3) 276.33 ± 153.9 285.71 ± 99.6 0.89
Creatinine (mg/dl) 0.65 ± 0.48 0.63 ± 0.36 0.92
Urine protein (g/24 h) 0.26*±0.21 0.56 ± 0.58 0.02
Uric acid (mg/dl) 5.88*±1.36 4.23 ± 1.16 0.03
AST (U/L) 30.83 ± 26.3 32.93 ± 20.3 0.86
ALT (U/L) 32.2 ± 34.2 24.5 ± 15.8 0.61
Alk. PO4ase (IU/L) 50.4*±20.7 81.43 ± 37.9 0.02
C3 (mg/dl) 0.7 ± 0.22 0.89 ± 0.46 0.12
C4 (mg/dl) 0.99*±0.1 0.24 ± 0.14 0.02
ANA No.(%) 8(100) 36(92.3)
Anti-dsDNA No.(%) 6(75) 27(69.2)
BMI: Body mass index, SLEDAI: Systemic Lupus Erythematosus Disease activity Index, SLICC: Systemic Lupus International Collaborating
Clinics. ESR: Erythrocyte sedimentation rate, Alk. PO4ase: Alkaline phosphatase, A/G: Albumin globulin ratio, C: complement, ANA:
Antinuclear antibody, ds DNA: double stranded DNA.
* Signiﬁcantly different from corresponding values at p< 0.05.
Figure 1 Plain X-ray chest (PA view) of a female SLE patient
with SLS showing bilateral elevated copula with right basal
atelectatic bands.
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0.39 L with a percentage predicted of 78.97 ± 9.51 and the
FEV1/FVC 97.78 ± 10.28%.
The HRCT of the 8 SLS patients was free of any parenchy-
mal disease. There was bilateral elevation of the diaphragm
copulae in 2 (25%) of SLS patients while the rest had elevation
of the right copula. Two patients had associated basal atelec-
tatic bands; otherwise the lung ﬁelds were clear. In SLE pa-
tients without SLS there was associated pulmonary
parenchymal disease seen on radiology in the form of minimal
pleural effusion and mild ILD in 3.
4. Discussion
Although respiratory manifestations of SLE are frequent, SLS
represents a rare complication and its pathogenesis and ther-
apy remain controversial, however it must be considered in a
patient with autoimmune disease and dyspnea. [25–27].
In the present study, SLS was present in 17.02% of SLE
cases. In 2 SLS patients, the copula was bilaterally elevated.
Figure 2 CT chest of a patient with SLS showing elevated right
hemi diaphragm and free pulmonary parenchyma.
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condition classically described in SLE patients [28] and is sel-
dom seen in other diseases [29]. Despite being rare, SLS must
be considered when SLE patients present by dyspnea without
heart insufﬁciency, anemia or diseases of the lung parenchyma
[30] A case report with SLS showed bilateral involvement with
reduced lung volumes [16]. In a Japanese SLE patient with
SLS, bilateral elevated diaphragms, clear lung ﬁelds with a
restrictive defect of PFT were present. Relation to lupus
ﬂare-up was suggested by the elevated ESR, leucopenia and
elevated anti-DNA titer [31]. In a report on three female
SLE cases with SLS, dyspnea and chest pain were present with
bilateral elevation of the diaphragm in two and a severe restric-
tive defect of the PFTs. However, the onset of pulmonary
manifestations occurred in the absence of a lupus ﬂare [32].
In SLE, the prevalence of SLS has been reported to be as
low as (1.77%) [21] and as high as 23%. It is noteworthy that
the published data on this condition are small in amount and it
is seldom seen in clinical practice [13]. A study on SLE patients
reported respiratory symptoms in 63% with 10% meeting the
deﬁnition for SLS [33] being 9.1% in another study [34].
In 87.23% of the SLE patients, dyspnea was due to pleu-
risy. The SLE clinical manifestations were comparable be-
tween those with and without SLS. The lung ﬁelds were clear
except for two SLS patients with an atelectatic band. Other
case reports on SLS found that these patients also presented
with arthritis, autoimmune hepatitis and polyserositis and
their chest xray showed elevated hemi-diaphragms and atelec-
tasis at both lung bases. The CT imaging revealed profound
low lung volumes with compressive atelectasis and no evidence
of ILD [25,35,36]. In a previous study, SLS was present in a
considerable subset of SLE patients (13.5%) in which serositis
was present in 50% [37]. The current patients all had dyspnea
which could explain the increased frequency of SLS compared
to the earlier work that also included SLE cases without dysp-
nea. In SLE patients with dyspnea or chest pain, SLS should
be looked for and PFTs are highly suggestive [37]. It has been
stated that respiratory symptoms, abnormal lung function,
and SLS are common in SLE. Clinicians should consider eval-
uation of SLS among symptomatic patients with long-standing
disease and a history of pleuritis [33].In the present study, the 24 h urine protein and alkaline
phosphatase were signiﬁcantly lower and the C4 level signif-
icantly normalized in SLE patients with SLS. Normal kidney
function tests have been reported in SLS patients [38]. These
favorable laboratory results support the lower disease activ-
ity and damage found in this subset of SLE patients. This
may further throw light on the reported good prognosis of
SLS cases and the favorable outcome [11]. Long-term prog-
nosis is good although respiratory failure can occur in some
cases [10]. The serum uric acid was signiﬁcantly higher in
SLE patients with SLS. There is no obvious explanation
other than the use of theophylline by all SLS patients and
2 other SLE cases. Theophylline is known to increase the
serum uric acid level. It has been reported that theophylline
increased the plasma concentrations of purine bases includ-
ing uric acid without a decreased urinary excretion in nor-
mal subjects [39]. In the present study, the anti-ds DNA
was comparable between those with and without SLS. It
has been reported that respiratory dysfunction appears to
be independent of the clinical course, duration and lupus
antibodies (ANA and anti-DNA) [35].
Restoring a near-normal lung function is an achievable goal
in SLS [40]. However, it may cause severe functional pulmon-
ary abnormalities and must be treated promptly and aggres-
sively in order to, at least, stabilize PFTs [1]. Prognosis is
generally good and most patients improve on increasing the
dose of steroids aimed at the subclinical respiratory myositis-
like process [35].
In conclusion, in SLE patients with dyspnea, SLS should be
looked for as it is present in a high proportion of cases. A lon-
gitudinal study on a larger scale of patients is recommended to
conﬁrm the ﬁndings and properly assess the outcome of this
subset and response to treatment strategies.Conﬂict of interest
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